Phase I study of cemiplimab, a human monoclonal anti-PD-1, in patients with unresectable locally advanced or metastatic cutaneous squamous cell carcinoma (CSCC): Longer follow-up efficacy and safety data
Titel:
Phase I study of cemiplimab, a human monoclonal anti-PD-1, in patients with unresectable locally advanced or metastatic cutaneous squamous cell carcinoma (CSCC): Longer follow-up efficacy and safety data
Auteur:
Owonikoko, T.K. Papadopoulos, K.P. Johnson, M.L. Gil MartÃn, M. Moreno, V. Salama, A.K. Calvo, E. Yee, N.S. Safran, H. Aljumaily, R. Mahadevan, D. Niu, J. Kal Mohan, K. Li, J. Stankevich, E. Mathias, M. Lowy, I. Fury, M.G. Babiker, H.M.